Holmseth S, Lehre K P, Danbolt N C
Centre of Molecular Biology and Neuroscience, Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, PO Box 1105, 0317, Oslo, Blindern, Norway.
Anat Embryol (Berl). 2006 Aug;211(4):257-66. doi: 10.1007/s00429-005-0077-6. Epub 2006 Jan 25.
Antibodies have been in widespread use for more than three decades as invaluable tools for the specific detection of proteins or other molecules in biological samples. In spite of such a long experience, the field of immunocytochemistry is still troubled by spurious results due to insufficient specificity of antibodies or procedures used. The importance of keeping a high standard is increasing because massive sequencing of entire genomes leads to the identification of numerous new proteins. All the identified proteins and their variants will have to be localized precisely and quantitatively at high resolution throughout the development of all species. Consequently, antibody generation and immunocytochemical investigations will be done on a large scale. It will be economically important to secure an optimal balance between the risk of publishing erroneous data (which are expensive to correct) and the costs of specificity testing. Because proofs of specificity are never absolute, but rather represent failures to detect crossreactivity, there is no limit to the number of control experiments that can be performed. The aims of the present paper are to increase the awareness of the difficulties in proving the specificity of immunocytochemical labeling and to initiate a discussion on optimized standards. The main points are: (1) antibodies should be described properly, (2) the labeling obtained with an antibody to a single epitope needs additional verification and (3) the investigators should be required to outline in detail how they arrive at the conclusion that the immunocytochemical labeling is specific.
三十多年来,抗体作为在生物样品中特异性检测蛋白质或其他分子的宝贵工具,得到了广泛应用。尽管有如此漫长的经验,但由于所用抗体或方法的特异性不足,免疫细胞化学领域仍然受到虚假结果的困扰。保持高标准的重要性日益增加,因为对整个基因组进行大规模测序会鉴定出众多新蛋白质。在所有物种的整个发育过程中,所有已鉴定的蛋白质及其变体都必须在高分辨率下进行精确定位和定量。因此,抗体的产生和免疫细胞化学研究将大规模开展。在发布错误数据的风险(纠正成本高昂)与特异性测试成本之间确保最佳平衡,在经济上具有重要意义。由于特异性证明永远不是绝对的,而只是代表未检测到交叉反应性,因此可以进行的对照实验数量没有限制。本文的目的是提高人们对证明免疫细胞化学标记特异性困难的认识,并引发关于优化标准的讨论。要点如下:(1)应正确描述抗体;(2)针对单个表位的抗体所获得的标记需要额外验证;(3)应要求研究人员详细说明他们如何得出免疫细胞化学标记具有特异性的结论。